Introduction of Typhoid Conjugate Vaccines in Africa and Asia

Kathleen M Neuzil; Andrew J Pollard; Anthony A Marfin

doi:10.1093/cid/ciy878

Introduction of Typhoid Conjugate Vaccines in Africa and Asia

Clin Infect Dis. 2019 Feb 15;68(Suppl 1):S27-S30. doi: 10.1093/cid/ciy878.

Authors

Kathleen M Neuzil¹, Andrew J Pollard², Anthony A Marfin³

Affiliations

¹ Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore.
² Oxford Vaccine Group, Department of Paediatrics, University of Oxford, United Kingdom.
³ PATH, Seattle, Washington.

Abstract

Typhoid fever continues to be a major public health concern, particularly in many low- and middle-income countries. The current threats of increasing antimicrobial resistance, urbanization, and climate change elevate the urgency for better prevention and control efforts for typhoid fever. In 2017, the results of ground-breaking research on typhoid conjugate vaccines (TCVs), the World Health Organization prequalification of a TCV, and global policy and financing decisions have set the stage for the introduction of TCVs into routine immunization programs in endemic countries. Country-level decision-making and program planning are critical for local uptake and sustainability.

Keywords: Africa; Asia; TyVAC; typhoid; vaccine.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Africa / epidemiology
Asia / epidemiology
Decision Making
Drug Resistance, Multiple, Bacterial
Humans
National Health Programs
Salmonella typhi / drug effects
Typhoid Fever / epidemiology*
Typhoid Fever / prevention & control*
Typhoid-Paratyphoid Vaccines / immunology*

Substances

Typhoid-Paratyphoid Vaccines